HK1139073A1 - - Google Patents

Info

Publication number: HK1139073A1
Authority: HK; Hong Kong
Prior art keywords: salt forms; phenyl; new salt; hsp90; polymorphs
Prior art date: 2007-03-01

Application number

HK10105737.5A

Other languages

English (en)

Inventor

Martin James Drysdale

Brian William Dymock

Christoph Krell

Michael Mutz

Holger Petersen

Weijia Zheng

Original Assignee

Novartis Ag

Vernalis R&D Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-01

Filing date

2010-06-09

Publication date

2010-09-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1139073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-06-09 Application filed by Novartis Ag, Vernalis R&D Ltd filed Critical Novartis Ag

2010-09-10 Publication of HK1139073A1 publication Critical patent/HK1139073A1/xx

Links

150000003839 salts Chemical group 0.000 abstract 6
102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 2
101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 abstract 2
238000009472 formulation Methods 0.000 abstract 2
NDAZATDQFDPQBD-UHFFFAOYSA-N luminespib Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 NDAZATDQFDPQBD-UHFFFAOYSA-N 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000011521 glass Substances 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
229940095064 tartrate Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

HK10105737.5A 2007-03-01 2010-06-09 HK1139073A1 (xx)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07103346		2007-03-01
PCT/EP2008/052443 WO2008104595A1 (en)	2007-03-01	2008-02-28	Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms

Publications (1)

Publication Number	Publication Date
HK1139073A1 true HK1139073A1 (xx)	2010-09-10

Family

ID=38134307

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK10105737.5A HK1139073A1 (xx)	2007-03-01	2010-06-09

Country Status (41)

Country	Link
US (3)	US8163747B2 (xx)
EP (2)	EP2131845B1 (xx)
JP (1)	JP2010520176A (xx)
KR (1)	KR20090122218A (xx)
CN (2)	CN102302500A (xx)
AR (1)	AR065519A1 (xx)
AT (1)	ATE552836T1 (xx)
AU (1)	AU2008220800B2 (xx)
BR (1)	BRPI0807992A2 (xx)
CA (1)	CA2678043A1 (xx)
CL (1)	CL2008000618A1 (xx)
CO (1)	CO6210828A2 (xx)
CR (1)	CR10989A (xx)
CY (1)	CY1113805T1 (xx)
DK (1)	DK2131845T3 (xx)
DO (1)	DOP2009000209A (xx)
EA (1)	EA017075B1 (xx)
EC (1)	ECSP099602A (xx)
ES (1)	ES2384906T3 (xx)
GE (1)	GEP20115309B (xx)
GT (1)	GT200900236A (xx)
HK (1)	HK1139073A1 (xx)
HR (1)	HRP20120535T1 (xx)
IL (1)	IL200401A0 (xx)
MA (1)	MA31204B1 (xx)
MX (1)	MX2009009233A (xx)
NI (1)	NI200900161A (xx)
NZ (1)	NZ578854A (xx)
PA (1)	PA8771101A1 (xx)
PE (1)	PE20090166A1 (xx)
PL (1)	PL2131845T3 (xx)
PT (1)	PT2131845E (xx)
RS (1)	RS52351B (xx)
SI (1)	SI2131845T1 (xx)
SM (1)	SMAP200900080A (xx)
TN (1)	TN2009000357A1 (xx)
TW (1)	TW200844102A (xx)
UA (1)	UA101950C2 (xx)
UY (1)	UY30943A1 (xx)
WO (1)	WO2008104595A1 (xx)
ZA (1)	ZA200905417B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200922595A (en) *	2007-10-12	2009-06-01	Novartis Ag	Organic compounds
TWI450898B (zh) *	2008-07-04	2014-09-01	Sigma Tau Res Switzerland Sa	具有抗腫瘤活性之芳基異唑化合物
US8309578B2 (en)	2008-11-25	2012-11-13	Nerviano Medical Sciences S.R.L.	Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
ES2578513T3 (es) *	2010-01-21	2016-07-27	Aprea Ab	Solución acuosa que comprende 3-quinuclidinona para el tratamiento de enfermedades hiperproliferativas, autoinmunes y cardiacas
WO2011102660A2 (en) *	2010-02-17	2011-08-25	Ildong Pharm Co., Ltd.	A novel 5-membered heterocycle derivatives and manufacturing process thereof
KR20120031854A (ko)	2010-09-27	2012-04-04	한국전자통신연구원	시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (en) *	2011-07-28	2013-01-31	Ildong Pharm Co.,Ltd.	Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) *	2015-07-31	2018-07-13	Les Laboratoires Servier	Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1771235B (zh) *	2003-02-11	2010-04-28	弗奈利斯(剑桥)有限公司	异噁唑化合物
US20060070405A1 (en) *	2004-10-06	2006-04-06	Anheuser-Busch, Inc.	Method for the production of amber glass with reduced sulfur-containing emissions
WO2008100985A2 (en)	2007-02-15	2008-08-21	Novartis Ag	Combination of lbh589 with other therapeutic agents for treating cancer
WO2010069458A1 (de)	2008-12-17	2010-06-24	Merck Patent Gmbh	Hexahalochromat(lll)-komplexe

2008
- 2008-02-28 PL PL08717228T patent/PL2131845T3/pl unknown
- 2008-02-28 JP JP2009551218A patent/JP2010520176A/ja active Pending
- 2008-02-28 US US12/529,090 patent/US8163747B2/en active Active
- 2008-02-28 AR ARP080100831A patent/AR065519A1/es not_active Application Discontinuation
- 2008-02-28 BR BRPI0807992-7A2A patent/BRPI0807992A2/pt not_active IP Right Cessation
- 2008-02-28 EP EP08717228A patent/EP2131845B1/en active Active
- 2008-02-28 CA CA002678043A patent/CA2678043A1/en not_active Abandoned
- 2008-02-28 UA UAA200908592A patent/UA101950C2/ru unknown
- 2008-02-28 UY UY30943A patent/UY30943A1/es not_active Application Discontinuation
- 2008-02-28 MX MX2009009233A patent/MX2009009233A/es active IP Right Grant
- 2008-02-28 ES ES08717228T patent/ES2384906T3/es active Active
- 2008-02-28 SI SI200830688T patent/SI2131845T1/sl unknown
- 2008-02-28 EP EP11192158.1A patent/EP2545921A3/en not_active Withdrawn
- 2008-02-28 AT AT08717228T patent/ATE552836T1/de active
- 2008-02-28 RS RS20120263A patent/RS52351B/en unknown
- 2008-02-28 KR KR1020097018126A patent/KR20090122218A/ko not_active Application Discontinuation
- 2008-02-28 CN CN201110226727.8A patent/CN102302500A/zh active Pending
- 2008-02-28 GE GEAP200811444A patent/GEP20115309B/en unknown
- 2008-02-28 PT PT08717228T patent/PT2131845E/pt unknown
- 2008-02-28 EA EA200901141A patent/EA017075B1/ru not_active IP Right Cessation
- 2008-02-28 NZ NZ578854A patent/NZ578854A/en not_active IP Right Cessation
- 2008-02-28 AU AU2008220800A patent/AU2008220800B2/en not_active Ceased
- 2008-02-28 DK DK08717228.4T patent/DK2131845T3/da active
- 2008-02-28 CN CN200880005490.7A patent/CN101636162A/zh active Pending
- 2008-02-28 WO PCT/EP2008/052443 patent/WO2008104595A1/en active Application Filing
- 2008-02-29 TW TW097107239A patent/TW200844102A/zh unknown
- 2008-02-29 CL CL200800618A patent/CL2008000618A1/es unknown
- 2008-02-29 PA PA20088771101A patent/PA8771101A1/es unknown
- 2008-02-29 PE PE2008000418A patent/PE20090166A1/es not_active Application Discontinuation
2009
- 2009-08-03 ZA ZA200905417A patent/ZA200905417B/xx unknown
- 2009-08-13 IL IL200401A patent/IL200401A0/en unknown
- 2009-08-21 CR CR10989A patent/CR10989A/es not_active Application Discontinuation
- 2009-08-28 TN TNP2009000357A patent/TN2009000357A1/fr unknown
- 2009-08-28 EC EC2009009602A patent/ECSP099602A/es unknown
- 2009-08-28 NI NI200900161A patent/NI200900161A/es unknown
- 2009-08-31 DO DO2009000209A patent/DOP2009000209A/es unknown
- 2009-08-31 MA MA32191A patent/MA31204B1/fr unknown
- 2009-08-31 GT GT200900236A patent/GT200900236A/es unknown
- 2009-09-01 CO CO09092694A patent/CO6210828A2/es not_active Application Discontinuation
- 2009-09-30 SM SM200900080T patent/SMAP200900080A/it unknown
2010
- 2010-06-09 HK HK10105737.5A patent/HK1139073A1/xx not_active IP Right Cessation
2012
- 2012-03-08 US US13/415,268 patent/US8487095B2/en active Active
- 2012-06-28 HR HRP20120535AT patent/HRP20120535T1/hr unknown
- 2012-07-09 CY CY20121100610T patent/CY1113805T1/el unknown
2013
- 2013-07-10 US US13/938,659 patent/US20130296556A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TN2009000357A1 (en)	2010-12-31
SMAP200900080A (it)	2010-01-19
CY1113805T1 (el)	2016-07-27
NI200900161A (es)	2010-07-27
AU2008220800B2 (en)	2012-02-16
US8163747B2 (en)	2012-04-24
CR10989A (es)	2010-03-01
AR065519A1 (es)	2009-06-10
BRPI0807992A2 (pt)	2014-06-17
UY30943A1 (es)	2008-10-31
CN102302500A (zh)	2012-01-04
GT200900236A (es)	2011-09-14
IL200401A0 (en)	2010-04-29
MX2009009233A (es)	2010-06-02
PL2131845T3 (pl)	2012-09-28
ES2384906T3 (es)	2012-07-13
WO2008104595A1 (en)	2008-09-04
ECSP099602A (es)	2009-12-28
US20120172592A1 (en)	2012-07-05
US8487095B2 (en)	2013-07-16
CL2008000618A1 (es)	2008-09-12
EP2131845B1 (en)	2012-04-11
GEP20115309B (en)	2011-10-25
CN101636162A (zh)	2010-01-27
ZA200905417B (en)	2010-05-26
PT2131845E (pt)	2012-07-10
ATE552836T1 (de)	2012-04-15
AU2008220800A1 (en)	2008-09-04
JP2010520176A (ja)	2010-06-10
DK2131845T3 (da)	2012-07-16
EP2545921A3 (en)	2013-04-10
CA2678043A1 (en)	2008-09-04
NZ578854A (en)	2012-03-30
SI2131845T1 (sl)	2013-02-28
UA101950C2 (ru)	2013-05-27
US20100093732A1 (en)	2010-04-15
EA200901141A1 (ru)	2010-04-30
MA31204B1 (fr)	2010-02-01
KR20090122218A (ko)	2009-11-26
EP2545921A2 (en)	2013-01-16
EA017075B1 (ru)	2012-09-28
DOP2009000209A (es)	2009-09-15
EP2131845A1 (en)	2009-12-16
RS52351B (en)	2012-12-31
US20130296556A1 (en)	2013-11-07
TW200844102A (en)	2008-11-16
HRP20120535T1 (hr)	2012-07-31
PE20090166A1 (es)	2009-03-14
PA8771101A1 (es)	2009-02-09
CO6210828A2 (es)	2010-10-20

Legal Events

Date	Code	Title	Description
2016-09-23	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20160228

Publication	Publication Date	Title
HK1139073A1 (xx)	2010-09-10
EA201101308A1 (ru)	2012-02-28	Применение ралфинамида для лечения биполярного расстройства
NO20085066L (no)	2009-02-06	4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
AU2018236805B2 (en)	2020-04-09	Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
NO20085064L (no)	2009-02-06	4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
IL183415A0 (en)	2007-09-20	Tartrate salt of isofagomine and methods of use
MY149731A (en)	2013-10-14	Compounds
UA88481C2 (ru)	2009-10-26	Донепезила фумарат, пригодный для получения фармацевтических композиций
EA201100063A1 (ru)	2011-10-31	СПОСОБ ПОЛУЧЕНИЯ ПИРИДО-ПИРИМИДИНОВЫХ ИНГИБИТОРОВ mTOR КИНАЗЫ, ИХ СОЛЕВЫХ ФОРМ И ИХ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ
NZ582284A (en)	2012-07-27	Carbamoyl-cyclohexanes for treating acute mania
MX2010007426A (es)	2010-08-18	Composiciones farmaceuticas para tratar trastorno del higado graso.
PH12019501566A1 (en)	2020-03-09	Amide compounds and use thereof
MX2009002906A (es)	2009-06-30	Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
AR060307A1 (es)	2008-06-04	Medicamentos
NZ593282A (en)	2013-06-28	Ethanamine compounds and their use for treating depression
MXPA04012685A (es)	2005-03-23	Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
MXPA05013717A (es)	2006-03-08	Derivados de acido 2-etoxi-2-fenilpropionico para el tratamiento de trastornos de lipido.
TW200635575A (en)	2006-10-16	Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome
EA201100826A1 (ru)	2011-10-31	Холиновые соли янтарной кислоты для лечения депрессий, страхов, шизофрении, нарушений сна и эпилепсии
TH123699A (th)	2013-05-23	สารประกอบ 4-[2-(2-ฟลูออโรฟีนอกซิเมธิล)เฟนิล]พิเพอริดีน
UA99789C2 (ru)	2012-09-25	Холиновые соли янтарной кислоты для лечения депрессии, тревожного состояния, шизофрении, расстройств сна и эпилепсии